This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pediatric Vaccines Market To 2017- Strategic Focus On Partnering As Licensing And Co-Development Accounted For 69% Of Deal-Making Activity From 2004-2011

NEW YORK, Feb. 6, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011

http://www.reportlinker.com/p0799192/Pediatric-Vaccines-Market-to-2017--Strategic-Focus-on-Partnering-as-Licensing-and-Co-Development-Accounted-for-69%-of-Deal-Making-Activity-from-2004-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011", which provides insights into global pediatric vaccines market forecast until 2017. The report provides an in-depth analysis of six vaccines which include hepatitis A, hepatitis B, polio, rotavirus, Mumps, Measles and Rubella (MMR) and Diphtheria, Tetanus and Pertussis (DTaP). The report also examines the immunization schedules for the covered vaccines. In addition, the report also includes insights into the vaccines Research and Development (R&D) pipeline.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research analysis shows that the overall global pediatric vaccines market was valued at $14 billion in 2010. The market is expected to witness a growth at a CAGR of 11.5% for the forecast period and will reach $24.3 billion by 2017. The global market revenues are expected to increase due to the introduction of new molecules which are currently in the regulatory filing stage and those in the later stages of development. The top pharmaceutical companies in the vaccines market are – GlaxoSmithKline, Sanofi, Pfizer, Novartis AG., Merck & co. Inc and SP-MSD. Approximately 88% of the market is covered by the above six companies.

Scope

- Data and analysis on the global pediatric vaccines market

1 of 11

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs